CombiGene AB (publ)

Headquartered in Lidingö, Sweden, CombiGene AB (publ) was established in 1999 and specializes in pioneering gene therapy solutions for severe, life-altering medical conditions. The company is currently advancing two primary gene therapy candidates in its pipeline. CG01, a treatment targeting epilepsy, is undergoing preclinical trials that include detailed biodistribution and toxicology assessments. Its second candidate, CGT2, is under development for addressing lipodystrophy. CombiGene also maintains strategic alliances, including a licensing and collaborative agreement with Lipigon Pharmaceuticals AB to create a gene therapy for partial lipodystrophy, and a partnership with Spark Therapeutics for the advancement of adeno-associated virus (AAV) based gene therapies.